Clinical Trial Update: Avanz Phleum Pratense Maintenance Dose [Phase 2, Phase 3]

View source ↗

Summary

This clinical trial update reports on the Phase 2/3 maintenance-dose study of Avanz Phleum Pratense for allergic rhinoconjunctivitis conducted by ALK-Abelló A/S…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinitis

Drugs mentioned

• Avanz Phleum Pratense (Phleum pratense pollen allergen extract)

Snippet

Sponsor: ALK-Abelló A/S | Conditions: Allergic Rhinoconjunctivitis | Phase 2, Phase 3 | Status: COMPLETED